Cortical spreading depolarisation (CSD) is a wave of abrupt and sustained near-complete breakdown of transmembrane ion gradient and mass depolarisation concentrically spreading at ~ 1.5 to 9.5 mm/min in the grey matter of the brain. In most cases, CSD suppresses the spontaneous activity of the brain tissue for several minutes. CSD was first reported in the rabbit brain by Leão. Prior to this pioneering work, Lashley posited that the scotoma of migraine visual aura could be explained by a wave of intense excitation propagating at 3 mm/min across the visual cortex. In 1958, Milner reported a possible association between CSD and migraine visual aura. The development of CSD during migraine aura is supported by blood flow changes and complex direct current magnetoencephalographic shifts. The most convincing evidence in humans for the association between CSD and migraine aura came from observed alterations in blood oxygenation level-dependent (BOLD) magnetic resonance imaging (MRI) compatible with the visual percept experienced during an episode of visual aura. Based on these studies, CSD is speculated as the pathophysiological mechanism underlying migraine aura. In addition, CSD has been shown to activate the trigeminal system, implying that CSD may be responsible for migraine headache and migraine aura.

Photophobia is a well-known accompanying symptom of migraine. During migraine attacks, photophobia can be improved by triptans (5-HT (serotonin) agonists) and calcitonin gene-related peptide (CGRP) antagonists.
receptor antagonists\textsuperscript{16–18}. However, photophobia-associated symptoms are experienced by migraineurs not only during attacks but also in the interictal period, thus persistently impairing the quality of life\textsuperscript{15}. Previous questionnaire-based studies demonstrated that patients affected by migraine with aura (MA) are more likely to exhibit these photophobia-associated symptoms than those affected by migraine without aura (MO) in both ictal and interictal phases\textsuperscript{19,20}. Furthermore, in BOLD MRI studies and a sound-induced visual illusion test, MA patients showed greater excitability of the occipital cortex to visual stimuli compared with MO patients\textsuperscript{19,21,22}. These findings raise the following two possibilities. Either CSD plays a role in forming a predisposition to photophobia or a hyperexcitable state in the occipital cortex is the primarily relevant pathophysiology in MA, which leads to the development of photophobia and CSD. However, this chicken-and-egg question is difficult to answer in clinical settings.

Migraine attacks render patients less mobile because migraineurs are aware that headache can be aggravated by physical activity. There are quantitative data showing that migraine reduces activity\textsuperscript{23}. Hence, locomotive activity serves as an index to evaluate functionality of migraine patients.

In the present study, we aimed to investigate whether CSD can cause trigeminal sensitisation, photophobia and hypomotility in mice. We measured heat pain threshold temperature and mouse locomotion in a light/dark box equipped with an infrared tracking system. Furthermore, we examined the effects of intraperitoneal administration of sumatriptan and olcegepant on CSD-induced changes in these measures. In particular, we first succeeded in delineating the temporal profiles of the effects of these agents on CSD-induced mobility alterations.

**Results**

**Experimental timelines, physiological parameters and CSD-related electrophysiological measures.** Five different experimental groups were included in the present study. Sham-operated mice administered with the vehicle were designated as the Sham-Vehicle group. Vehicle-treated mice that underwent the CSD procedure were referred to as the CSD-Vehicle group. Those subjected to both CSD and pharmacological treatment were designated in accordance with the administered agent and dose: the CSD-Sumatriptan, CSD-Olcegepant 0.25 and CSD-Olcegepant 1.0 groups.

Experimental timelines for facial heat pain threshold temperature measurement and locomotive assessment are shown in Fig. 1a, b, respectively. Craniotomies for CSD induction and installation of experimental probes were performed at the CSD-Vehicle group. Those subjected to both CSD and pharmacological treatment were designated in accordance with the administered agent and dose: the CSD-Sumatriptan, CSD-Olcegepant 0.25 and CSD-Olcegepant 1.0 groups.

Experimental timelines for facial heat pain threshold temperature measurement and locomotive assessment are shown in Fig. 1a, b, respectively. Craniotomies for CSD induction and installation of experimental probes were performed at the CSD-Vehicle group. Those subjected to both CSD and pharmacological treatment were designated in accordance with the administered agent and dose: the CSD-Sumatriptan, CSD-Olcegepant 0.25 and CSD-Olcegepant 1.0 groups.

Experimental timelines for facial heat pain threshold temperature measurement and locomotive assessment are shown in Fig. 1a, b, respectively. Craniotomies for CSD induction and installation of experimental probes were performed at the CSD-Vehicle group. Those subjected to both CSD and pharmacological treatment were designated in accordance with the administered agent and dose: the CSD-Sumatriptan, CSD-Olcegepant 0.25 and CSD-Olcegepant 1.0 groups.

Experimental timelines for facial heat pain threshold temperature measurement and locomotive assessment are shown in Fig. 1a, b, respectively. Craniotomies for CSD induction and installation of experimental probes were performed at the CSD-Vehicle group. Those subjected to both CSD and pharmacological treatment were designated in accordance with the administered agent and dose: the CSD-Sumatriptan, CSD-Olcegepant 0.25 and CSD-Olcegepant 1.0 groups.
Temporal profiles of CSD-induced facial hyperalgesia. In the Sham-Vehicle group, no significant change was found in heat pain threshold temperature at 3 h and 24 h from the baseline value (Fig. 2). With regard to comparison between the Sham-Vehicle and CSD-Vehicle groups, the two-way analysis of variance (ANOVA) revealed a significant main effect of CSD induction ($F(1, 292) = 4.728, P = 0.0308$) with a significant interaction between CSD induction and observation time ($F(2, 292) = 5.442, P = 0.0048$; Fig. 2). At 24 h after CSD, heat pain threshold temperature was significantly lower in the CSD-Vehicle group than in the Sham-Vehicle group (mean difference: $-0.86 [95\% \text{CI} -1.39 \text{ to} -0.32] ^\circ C, P = 0.0004$, Bonferroni’s multiple comparison test; Fig. 2). Sumatriptan significantly altered the time course of the CSD-induced heat pain threshold temperature by inhibiting the CSD-induced reduction ($F(1, 245) = 6.332, P = 0.0125$; Fig. 2). With regard to olcegepant, the two-way ANOVA did not detect an overall effect of olcegepant treatment on heat pain threshold temperature, but a significant difference was found at 24 h after CSD between the CSD-Vehicle and CSD-Olcegepant 1.0 groups (mean difference: $-0.53 [95\% \text{CI} -1.01 \text{ to} -0.05] ^\circ C, P = 0.0244$, Bonferroni’s multiple comparison test; Fig. 2).

Table 1. Physiological and CSD-related electrophysiological parameters among experimental groups.

| Basic physiological parameters of light/dark test | Sham-Vehicle | CSD-Vehicle | CSD-Sumatriptan | CSD-Olcegepant 0.25 | CSD-Olcegepant 1.0 |
|-------------------------------------------------|--------------|-------------|-----------------|---------------------|-------------------|
| HR (bpm)                                        | 437 ± 25     | 472 ± 34    | 469 ± 30        | 466 ± 37            | 464 ± 21          |
| SBP (mmHg)                                      | 73 ± 13      | 67 ± 13     | 65 ± 9          | 68 ± 9              | 74 ± 14           |
| Body weight (g)                                 | 22.4 ± 0.8   | 25.8 ± 1.5  | 25.8 ± 1.2      | 24.7 ± 0.8          | 23.3 ± 0.4        |

| Electrophysiological parameters of light/dark test | Sham-Vehicle | CSD-Vehicle | CSD-Sumatriptan | CSD-Olcegepant 0.25 | CSD-Olcegepant 1.0 |
|-------------------------------------------------|--------------|-------------|-----------------|---------------------|-------------------|
| Propagation velocity (mm/min)                   | N/A          | 4.4 ± 0.3   | 4.2 ± 0.2       | 4.3 ± 0.3           | 4.3 ± 0.2         |
| FWHM (s)                                        | N/A          | 47.5 ± 2.5  | 45.3 ± 3.3      | 45.7 ± 2.9          | 45.7 ± 2.9        |
| Max. DC change (mV)                             | N/A          | −8.2 ± 0.9  | −7.8 ± 0.6      | −9.1 ± 1.0          | −9.6 ± 1.0        |

| Basic physiological parameters of heat pain test | Sham-Vehicle | CSD-Vehicle | CSD-Sumatriptan | CSD-Olcegepant 0.25 | CSD-Olcegepant 1.0 |
|------------------------------------------------|--------------|-------------|-----------------|---------------------|-------------------|
| HR (bpm)                                        | 444 ± 13     | 431 ± 10    | 430 ± 4         | 432 ± 15            | 444 ± 8           |
| SBP (mmHg)                                      | 65 ± 13      | 67 ± 2      | 74 ± 4          | 56 ± 1              | 61 ± 3            |
| Body weight (g)                                 | 22.1 ± 0.3   | 22.4 ± 0.2  | 22.5 ± 0.6      | 20.6 ± 0.2          | 22.1 ± 0.2        |

| Electrophysiological parameters of heat pain test | Sham-Vehicle | CSD-Vehicle | CSD-Sumatriptan | CSD-Olcegepant 0.25 | CSD-Olcegepant 1.0 |
|------------------------------------------------|--------------|-------------|-----------------|---------------------|-------------------|
| Propagation velocity (mm/min)                   | N/A          | 4.3 ± 0.2   | 4.3 ± 0.1       | 4.5 ± 0.2           | 4.2 ± 0.2         |
| FWHM (s)                                        | N/A          | 49.7 ± 3.2  | 48.1 ± 2.7      | 57.2 ± 5.2          | 47.4 ± 2.2        |
| Max. DC change (mV)                             | N/A          | −6.5 ± 0.4  | −7.9 ± 1.2      | −6.5 ± 1.0          | −6.1 ± 1.0        |

Figure 2. Temporal profiles of facial hyperalgesia. The ordinate indicates facial heat pain threshold temperature ($^\circ C$). The two-way repeated measures analysis of variance was used to evaluate the effects of cortical spreading depolarisation (CSD) induction and pharmacological interventions on the parameters. Multiple comparisons were made by Bonferroni’s test (*$P < 0.05$, **$P < 0.01$ vs. First segment; ***$P < 0.001$ vs. CSD-Vehicle group at 24 h). B Baseline, 3 h after CSD, 24 h after CSD, Sham-Veh Sham-Vehicle group, CSD-Veh CSD-Vehicle group, CSD-Suma CSD-Sumatriptan group, CSD-Olc0.25 CSD-Olcegepant 0.25 group, CSD-Olc1.0 CSD-Olcegepant 1.0 group.
CSD-induced reduction in total time spent in the light zone. Our preliminary assay revealed that normal male mice spent approximately 60% of the entire time in the dark zone under the lighting condition stated in the Methods section. Hence, our lighting condition was suitable for assessing photophobia.

Compared with the Sham-Vehicle group, the CSD-Vehicle group spent significantly less time in the light zone (121.9 ± 38.9 s vs. 412.2 ± 103.8 s, \( P = 0.0021 \), Dunn's multiple comparison test; Fig. 3). In the comparison among CSD-subjected mice, the total time spent in the light zone was significantly longer in sumatriptan-treated versus vehicle-treated mice (CSD-Sumatriptan group: 442.4 ± 71.9 s vs. CSD-Vehicle group: 121.9 ± 38.9 s, \( P = 0.0021 \), Dunn's multiple comparison test; Fig. 3). A trend was observed that olcegepant exerted an ameliorating effect at 0.25 mg/kg (CSD-Olcegepant 0.25 group: 382.4 ± 118.6 s, \( P = 0.0664 \) vs. CSD-Vehicle group, Dunn's multiple comparison test; Fig. 3). At a dose of 1 mg/kg, olcegepant significantly increased the total time spent in the light zone versus vehicle (CSD-Olcegepant 1.0 group: 416.1 ± 101.1 s, \( P = 0.0184 \), Dunn's multiple comparison test; Fig. 3).

CSD-induced changes in ambulatory time and ambulatory distance in the light zone. In the light zone, the CSD-Vehicle group exhibited a significantly shorter ambulatory time than the Sham-Vehicle group (9.6 ± 1.8 s vs. 27.3 ± 5.0 s, \( P = 0.0024 \), Dunn's multiple comparison test; Fig. 4a). Sumatriptan and olcegepant (1.0 mg/kg) significantly improved the shortening of ambulatory time (24.7 ± 3.6 s in the CSD-Sumatriptan group, \( P = 0.0055 \) and 23.7 ± 4.8 s in the CSD-Olcegepant 1.0 group, \( P = 0.034 \), Dunn's multiple comparison test; Fig. 4a). Similarly, the ambulatory distance travelled was shorter in the CSD-Vehicle group than in the Sham-Vehicle group (299 ± 59 cm vs. 911 ± 161 cm, \( P = 0.0118 \), Dunn's multiple comparison test; Fig. 4b). Sumatriptan and olcegepant (1.0 mg/kg) reversed the CSD-induced reduction in ambulatory distance (893 ± 150 cm in the CSD-Sumatriptan group, \( P = 0.0026 \) and 885 ± 188 cm in the CSD-Olcegepant 1.0 group, \( P = 0.0085 \), Dunn's multiple comparison test; Fig. 4b).

CSD-induced changes in ambulatory time and ambulatory distance in the dark zone. In the dark zone, the CSD-Vehicle group was significantly less ambulatory compared with the Sham-Vehicle group with regard to both time (15.8 ± 2.6 s vs. 38.1 ± 4.3 s, \( P = 0.0014 \), Dunn's multiple comparison test; Fig. 4a) and distance (539 ± 76 cm vs. 1,331 ± 164 cm, \( P = 0.0023 \), Dunn's multiple comparison test; Fig. 4b). All pharmacological interventions significantly prevented the CSD-induced reduction in ambulatory time (37.9 ± 10.7 s in the CSD-Sumatriptan group, \( P = 0.0292 \); 28.8 ± 3.2 s in the CSD-Olcegepant 0.25 group, \( P = 0.0396 \); and 34.7 ± 4.4 s in the CSD-Olcegepant 1.0 group, \( P = 0.005 \), Dunn's multiple comparison test; Fig. 4a). In addition, all pharmacological interventions significantly ameliorated the CSD-induced decrease in distance travelled (1,296 ± 346 cm in the CSD-Sumatriptan group, \( P = 0.027 \); 1,038 ± 108 cm in the CSD-Olcegepant 0.25 group, \( P = 0.0426 \); and 1,264 ± 169 cm in the CSD-Olcegepant 1.0 group, \( P = 0.0034 \), Dunn's multiple comparison test; Fig. 4b).

Comparison of CSD-induced changes in ambulatory time proportion between the light and dark zones. Ambulatory time proportion of total time spent in the light zone did not differ among the groups, although the CSD-Vehicle group exhibited an increasing trend compared with the Sham-Vehicle group (Fig. 5, red bars). In the dark zone, the CSD-Vehicle group exhibited a significant decrease compared with the Sham-Vehicle group (1.0 ± 0.2% vs. 3.1 ± 0.6%, \( P = 0.0029 \), Dunn's multiple comparison test; Fig. 5, blue bars). This CSD-induced reduction in ambulatory time proportion was reversed by sumatriptan and olcegepant at 1.0 mg/kg (2.9 ± 0.8% in the CSD-Sumatriptan group and 2.8 ± 0.5% in the CSD-Olcegepant 1.0 group, \( P = 0.0156 \), Dunn's multiple comparison test; Fig. 5, blue bar 4).
Figure 4. Ambulatory time and ambulatory distance in the light and dark zones. Red and blue bars represent the light and dark data, respectively. (a) The ordinate indicates the ambulatory time (s). (b) The ordinate indicates the ambulatory distance (cm). Statistical analysis was performed using the Kruskal–Wallis test, followed by Dunn’s multiple comparison test. *P < 0.05, **P < 0.01 versus CSD-Vehicle group. N = 8 in each group.

Figure 5. Comparison of cortical spreading depolarisation (CSD)-induced changes in ambulatory time proportion between the light and dark zones. Red and blue bars represent the light and dark data, respectively. The ordinate indicates the ambulatory time proportion (%). Statistical analysis was performed using the Kruskal–Wallis test, followed by Dunn’s multiple comparison test. *P < 0.05, **P < 0.01 versus CSD-Vehicle group. N = 8 in each group.
Temporal profiles of the ambulatory time in the light zone. With regard to the comparison between the Sham-Vehicle and CSD-Vehicle groups, the two-way ANOVA revealed significant main effects of observation time ($F(2,28) = 17.26, P < 0.0001$) and CSD induction ($F(1,14) = 11.15, P = 0.0049$) on ambulatory time, whereas no significant interaction between them was observed (Fig. 6a). Sumatriptan exerted a significant main effect on ambulatory time ($F(1,14) = 12.53, P = 0.0033$), but no significant interaction was noted between sumatriptan treatment and observation time (Fig. 6a). Significant interaction was not found between these factors ($P = 0.2231$).

On the other hand, olcegepant showed no significant main effect on ambulatory time, although a significant difference was noted between the CSD-Vehicle and CSD-Olcegepant 1.0 groups only in the third segment ($\text{mean difference} -7.03 [95\% \text{ CI} -12.56 \text{ to } -1.49] \text{ s}, P = 0.0098; \text{Fig. 6a})$.

Temporal profiles of the ambulatory distance in the light zone. With regard to the comparison between the Sham-Vehicle and CSD-Vehicle groups, the two-way ANOVA detected significant main effects of observation time ($F(2, 28) = 10.56, P = 0.0004$) and CSD induction ($F(1, 14) = 12.86, P = 0.003$) on ambulatory distance in the light zone, but no significant interaction was found between these factors (Fig. 6b). Significant ameliorating effects of sumatriptan ($F(1, 14) = 12.4, P = 0.0034$) and olcegepant ($F(2, 21) = 3.908, P = 0.00361$) were noted on ambulatory distance in the light zone (Fig. 6b). No significant interaction was found between observation time and either of these drugs.

Temporal profiles of the ambulatory time in the dark zone. Comparing the Sham-Vehicle and CSD-Vehicle groups, the two-way ANOVA found significant main effects of observation time ($F(2, 28) = 15.21, P < 0.0001$) and CSD induction ($F(1, 14) = 20.12, P = 0.0005$) on ambulatory time in the dark zone, whereas no significant interaction was detected (Fig. 6a). The CSD-induced reduction in ambulatory time in the dark zone was improved by both sumatriptan and olcegepant. Sumatriptan exerted a significant main effect ($F(1, 14) = 6.445, P = 0.0236$) with a significant interaction with observation time ($F(2, 28) = 4.907, P = 0.0149$; Fig. 6a). A significant main effect of olcegepant was found ($F(2, 21) = 7.942, P = 0.0027$). No significant interaction was noted between observation time and olcegepant treatment (Fig. 6a).

Temporal profiles of the ambulatory distance in the dark zone. With regard to the comparison between the Sham-Vehicle and CSD-Vehicle groups, the two-way ANOVA detected significant main effects of observation time ($F(2, 28) = 18.84, P = 0.0001$) and CSD induction ($F(1, 14) = 19.68, P = 0.006$) on ambulatory distance in the dark zone, whereas no significant interaction was found between these factors (Fig. 6b). The CSD-induced reduction in ambulatory distance in the dark zone was ameliorated by both sumatriptan and olcegepant. Sumatriptan exerted a significant main effect ($F(1, 14) = 6.833, P = 0.0204$) with a significant interaction with observation time ($F(2, 28) = 7.567, P = 0.0024$; Fig. 6b). A significant main effect of olcegepant on ambulatory distance was detected ($F(2, 21) = 8.969, P = 0.0015$), but no interaction was observed with observation time (Fig. 6b).
Comparison of the average ambulatory speed among experimental groups. The average ambulatory speed was measured in each mouse to examine whether CSD induction or pharmacological interventions caused motor impairments. Significant between-group differences were not observed in average ambulatory speed (Sham-Vehicle group: 52.6 ± 0.7 cm/s, CSD-Vehicle group: 54.0 ± 1.1 cm/s, CSD-Sumatriptan group: 52.4 ± 0.9 cm/s, CSD-Olcegepant 0.25 group: 53.3 ± 1.0 cm/s and CSD-Olcegepant 1.0 group: 57.8 ± 0.8 cm/s, P = 0.8224, Kruskal–Wallis test).

Discussion

Our data on facial heat pain threshold temperature revealed the presence of facial hyperalgesia at 24 h after CSD induction. In addition, our locomotive analysis demonstrated that light aversion was present 24 h after CSD induction, as evidenced by a significantly reduced total time spent in the light zone. Moreover, CSD-affected mice presented significantly decreased values for ambulatory time and distance in both light and dark zones in similar profiles. Such reductions in ambulatory time and ambulatory distance could not be explained by motor impairment, because average ambulatory speed was not altered by CSD. The proportions of ambulatory time per total time spent significantly decreased in the dark zone, but tended to increase in the light zone. The former finding is reminiscent of the typical ictal behaviour pattern of migraineurs who prefer resting in a dark environment. The latter can be interpreted as an attempt of CSD-subjected mice to promptly evade from the aversive environment (light zone) to the more comfortable one (dark zone). In this sense, this observation seems to lend further support to the tenet that CSD is causative of photophobia. From a therapeutic perspective, both sumatriptan and olcegepant were effective in ameliorating facial hyperalgesia, photophobic behaviour and locomotive hypoactivity in the light and dark zones. Moreover, we demonstrated dose-dependent effects of olcegepant on these abnormalities.

CSD has been demonstrated to sensitis the trigeminal system12–14,24, although this has yet to be validated in humans. Facial hyperalgesia is a representative manifestation of trigeminal sensitisation15,16. We previously demonstrated that facial hyperalgesia was induced in an inflammatory soup-based headache model17. A salient finding in the present study is that CSD-induced trigeminal sensitisation persists for at least 24 h. CSD-subjected mice were inferred to be still in a condition similar to the ictal state of migraine at this timepoint. This tenet is reinforced by the fact that the facial hyperalgesia was reversed by acute anti-migraine drugs, sumatriptan and olcegepant.

Patients affected by migraine regard photophobia as the most bothersome accompanying symptom18. In contemporary society, people are prone to be exposed to a variety of light sources. For many people, working in front of a visual display terminal and using a smartphone on multiple occasions on a daily basis are inevitable. This holds true especially for young individuals, among whom migraine causes the highest disability rates28,29. Hence, proper management of ictal photophobic symptoms should decrease the migraine-induced loss of productivity by improving the functionality in patients with migraine30,31. The present study provides therapeutically important information that sumatriptan and olcegepant are efficacious in reversing CSD-induced photophobic behaviour.

Along with photophobia, reduced activity seems to affect a migraine-associated decrease in functionality. A quantitative study using ambulatory accelerometer reported that migraine reduces overall body motility in a manner dependent on attack severity32. The light/dark box test is traditionally used mainly to assess anxiety, activity and exploration33. With regard to the applicability of this experimental system to migraine research, Recober et al.34 succeeded in characterising the temporal profile of CGRP-induced behavioural pattern and light aversion. In the present study, we demonstrated that hypomotility existed in both light and dark zones 24 h after CSD, thus indicating that hypomotility is independent of photophobia. Of particular relevance, our study delineated the trajectories of the behavioural response to sumatriptan and olcegepant treatments. Our data showed that sumatriptan and olcegepant (1.0 mg/kg) exerted significant efficacy only in the second or third segments (20–40 min after treatment induction). Hence, these drugs seem to have therapeutic lags ranging from 20 to 30 min when administered intraperitoneally.

Collectively, sumatriptan and olcegepant were effective in ameliorating CSD-induced facial hyperalgesia, photophobia and hypomotility. A dose of 0.6 mg/kg sumatriptan used in our experiment has been shown to be effective in alleviating nitroglycerin-induced thermal and mechanical hyperalgesia34 and CGRP-induced photophobia35 in mice. Compared with sumatriptan, olcegepant has been used much less in rodent studies. Nevertheless, the efficacy of olcegepant against our measures seems to be specific, because its dose dependency was confirmed.

With regard to the efficacy of both drugs in CSD-induced facial hyperalgesia and hypomotility, interpreting that mouse locomotion was improved as a result of pain relief seems reasonable. What is the mechanism whereby sumatriptan and olcegepant alleviate CSD-induced photophobic behaviour? Noseda et al.15 postulated that the convergence of photic signals from intrinsically photosensitive retinal ganglion cells onto the trigemino-vascular thalamocortical pathway plays an important role in the intensification of headache by light. By using single-unit recording and neural tract tracing in the rat, they identified dura-sensitive neurons in the posterior thalamus whose activity was modulated also by light and whose axons projected extensively to the somatosensory, visual and associative cortices36. Hence, sumatriptan and olcegepant are deduced to act somewhere along this neural pathway in our experimental model. Intriguingly, 5-HT1D and 5-HT1D receptors are enriched in the occipital cortex37. Moreover, recent evidence shows that extensive localisation of CGRP and its receptor exists in the central nervous system38,39. These findings raise the possibility that sumatriptan and olcegepant exerted their efficacy by a central mechanism. On the other hand, the ameliorating effect could possibly be exerted by a peripheral mechanism. Triptans is generally accepted to exert their anti-migraine efficacy by acting on 5-HT1D receptors located at trigeminal terminals40,41. The localization of 5-HT1D receptors on CGRP-positive trigeminal ganglion neurons has been demonstrated in humans42, and 5-HT1D receptor blockade has been shown to block CGRP...
release from trigeminal terminals. In addition, recent experimental data have highlighted the action of CGRP on a subset of trigeminal fibres innervating the dura. The ability of sumatriptan and olcegepant to suppress pain signals at the nociceptor level may attenuate photophobia, as well as headache, because of decreased nociceptive input to the thalamus. Hence, determining the sites of action of these drugs in our experiments is difficult. Although sumatriptan does not readily penetrate the blood–brain barrier, the invasive nature of our surgical procedure might have compromised its integrity. In this regard, using monoclonal antibodies targeting CGRP or its receptor and less invasive surgical techniques for inducing CSD may provide a clearer answer to this problem. The use of monoclonal antibodies may be beneficial in terms of target specificity as well, especially because we were able to obtain robust effects of olcegepant at the higher dose. Our experimental system is useful for assessing therapeutic efficacy with regard to trigeminal sensitisation, light aversion and hypoactivity in murine migraine models.

The present study has several limitations. First, since the assessment of locomotion in the light and dark was performed only at 24 h after CSD induction, how photophobia and hypomotility develop temporally after CSD remains unclear. The invasive nature of the CSD-related surgery and potential residual effects of the anaesthesia rendered the accurate evaluation of the mouse motility at earlier timepoints difficult. We utilised KCl solution to evoke CSD, because this is the most reliable method for inducing CSD in our experience. In this regard, the possibility that KCl per se served as noxious stimulation to the surrounding trigeminal terminals cannot be completely ruled out. Second, we used only male mice in the present study, because CSD biology has been shown to be affected by the oestrous cycle and sex steroid hormones. However, this might be a weakness, because migraine is approximately three times more common in females than in males.

In summary, the present study provided quantitative evidence that trigeminal sensitisation, photophobic behaviour and reduced locomotion were present at 24 h after CSD induction. Moreover, we demonstrated that sumatriptan and olcegepant were efficacious in reversing such CSD-induced abnormalities with detailed temporal profiles of their efficacy for hypomobility. From a clinical viewpoint, the present study supports the view that CSD is causative of headache (trigeminal sensitization), photophobia and hypomotility, all of which impair quality of life in migraine patients. As for the chicken-and-egg question on the relationship between migraine aura and photophobia stated above, our findings may explain why patients with MA are more likely to exhibit photophobic symptoms than those with MO.

Methods

Animals. The present study was approved by the Laboratory Animal Care and Use Committee of Keio University (No. 14084). All experimental procedures were performed in accordance with the university’s protocols and EC Directive 86/609/EEC for animal experiments. Male C57BL/6 mice aged 8–10 weeks were purchased from CLEA Japan Inc. (Fujinomiya, Japan). A total of 86 mice were examined. They were housed in an ambient specific-pathogen-free condition with a 12-h light/dark cycle; free access to food and water was allowed.

Drug administration. Sumatriptan succinate (Tokyo Chemical Industry Co., Ltd., Tokyo, Japan), dissolved in normal saline, was intraperitoneally administered at a dose of 0.6 mg/kg through a 26-gauge needle. The amount of diluent was 10 µL/g. Olcegepant (MedChemExpress, Mammoth Junction, NJ), initially dissolved in dimethylsulfoxide at 0.025 mg/µL, was 250-fold diluted in normal saline. Intraperitoneal injections at a dose of either 1.0 mg/kg or 0.25 mg/kg were performed using a 26-gauge needle. Normal saline without dimethylsulfoxide was used as the vehicle. Our preliminary data showed that mouse locomotion was affected by an intraperitoneal injection with normal saline, particularly in the 60-min post-injection period. Hence, sham-operated mice with an intraperitoneal injection of normal saline were used as controls in locomotion assays.

CSD induction. Under isoflurane anaesthesia (1–2%), the mouse head was fixed in a stereotaxic apparatus. Systolic blood pressure and heart rate were monitored at the tail artery with a non-invasive blood pressure monitor (MK-2000ST; Muromachi Kikai Co., Ltd., Tokyo, Japan). Body temperature was maintained at approximately 37 °C using a heating-pad and thermocontroller (BWT-100; Bioresearch Center Co., Ltd., Nagoya, Japan).

The detailed procedures of the electrophysiological recording were described previously. Schematic representations for surgery are presented in Fig. 1. Briefly, three holes were drilled in the skull over the left hemisphere. A posterior hole, approximately 1 mm in diameter centred at the coordinates of 5 mm posterior and 2 mm lateral to the bregma, was made for the KCl stimulation. The parietal hole (2 mm lateral and 2 mm caudal to the bregma) and the frontal hole (2 mm lateral and 2 mm rostral to the bregma) were made for the placement of the recording electrodes. The diameters of these holes were less than 1 mm. Two Ag/AgCl DC electrodes (tip diameter = 200 µm, EEG-5002Ag; Bioresearch Center Co., Ltd.) were placed on the dura at the parietal (proximal) and frontal (distal) holes, respectively, and fixed with dental cement. A DC potential was applied at 1–100 Hz and digitised at 1 kHz with a differential head stage and differential extracellular amplifier (Model 4,002 and EX1; Dagan Co., Minneapolis, MN, USA). In the area close to the parietal hole (4 mm lateral and 2 mm posterior to the bregma), the probe (BFS2; Advance Co., Ltd., Tokyo, Japan) of a laser Doppler flowmeter (LDF; ALF 21, Advance Co., Ltd.) was installed on the intact skull to monitor the regional cerebral blood flow (rCBF). Continuous recordings of the DC potential and rCBF were stored on a multi-channel recorder (PowerLab 8/30; ADInstruments, Ltd., Sydney, Australia.), and LabChart software (ADInstruments, Ltd.) was used for off-line analysis as reported previously. After confirmation that all parameters had been stable for at least 10 min, CSD was induced by chemical stimulation with KCl solution (1.0 mol/L, 5 µL) onto the dura. The appearance of CSD was confirmed by the demonstration of a distinct DC potential deflection, typical fluctuation of rCBF, propagation to the distal portion and the suppression of electroencephalography (Fig. 1d). The CSD induction was performed five times after washing the cortical surface with normal saline to prevent residual KCl solution.
from acting on the nociceptors in the surrounding tissue. After the surgery, all electrodes were removed, and
the craniotomies were closed off with dental cement. In sham-operated mice, all these surgical procedures were
carried out except for the chemical stimulation with KCl solution and DC electrodes insertion. LDF was stalled
on the skull to confirm no occurrence of CSD.
CSD-related electrophysiological parameters (propagation velocity, DC potential decrease and FWHM) were
examined. CSD propagation velocity was calculated from the latency and distance between the proximal and
distal electrodes. The maximum decrease in DC potential and FWHM were determined from the curves recorded
at the distal electrode.

**Facial heat pain threshold temperature measurement.** The detailed protocol for heat pain thresh-
old temperature was described elsewhere\(^27\). Briefly, after acclimation to an experimental apparatus that restricted
body mobility, save for head movement and facial hair removal, a pair of Peltier module bars with surface tem-
perature regulated between 36 and 56 °C was applied to the face bilaterally. The bar surface temperature was
gradually increased from 36 °C by 1 °C/4 s until face withdrawal. Mouse behaviours were monitored using a
video recorder (Panasonic, Kadoma, Japan). The video was analysed by an examiner blind to the identity of the
animals. The lowest temperature at which a mouse turned the head away from the bars was recorded as the heat
pain threshold temperature. In each session, measurement of the threshold temperature was repeated five times.
The measurement was carried out before surgery, and 3 and 24 h after surgery. At 24 h after surgery, the timing
of measurement was between 10 and 30 min after administration with a drug or vehicle.

**Mouse locomotion analysis in the light and dark zones.** Mouse behaviours were continuously moni-
tored in an open field chamber (27 cm wide × 27 cm deep × 20.3 cm high) with three sets of 16-beam infrared
arrays (two sets of perpendicular beams crossed at a height of 1.0 cm to detect mouse location and locomotion,
and the third beam crossed the width of the chamber at a height of 7.3 cm to detect vertical activity; Med Asso-
ciates, Fairfax, VT). The testing chamber was placed inside a windowless cabinet. The testing field was equally
compartmented in light and dark zones by a dark insert (Med Associates). Mice could move freely between the
two zones through an orifice (5.2 cm × 6.8 cm) in the dark insert. The light intensity measured at a height of 2 cm
in the light zone was 540 lx, whereas the intensities measured in the dark zone were 380 lx immediately inside
the orifice, 20 lx at the centre, and 5 lx at the corners. Mouse activity was analysed using a computer equipped
with Activity Monitor v6.02 (Med Associates).

On the day mice were taken from the animal facility, they were allowed to acclimatise to the test chamber for
10 min with the overhead lighting off, then for 30 min with the lighting on. This acclimation process was repeated
on the subsequent two days at an interval of 24 h. Previous studies revealed that daily repeated testing is possible
up to three to four times a week without affecting the exploratory behavioural pattern\(^57,58\). On the day of the CSD
or sham operation, the acclimation was carried out prior to the operation. At 24 h after CSD or sham operation,
mice were intraperitoneally administered with either an active drug or vehicle (Fig. 1a). Subsequently, they were
put into the testing chamber with the lighting off for 10 min, and their locomotive activity was recorded for the
following 30 min with the lighting on. For all mice examined, behavioural testing was carried out between 10:00
and 18:00 in a quiet room.

**Assessment of mouse locomotion.** The effects of drug administration on mouse locomotion in both
compartments were evaluated using several parameters relevant to movement. The locomotion assessment was
started at 10 min after administration with a drug or vehicle (Fig. 1b). In this experiment, when mice moved
out of a 6.35 cm × 6.35 cm square box around them within 0.5 s, their movements were defined as ambulatory.
Ambulatory distance (cm) was defined as the total distance travelled during the ambulatory movement status.
Ambulatory time proportion was calculated by dividing ambulatory time by total time spent in a zone. Ambu-
latory average velocity (cm/s) was calculated as ambulatory distance divided by ambulatory time, which was
averaged over the whole 30-min test period. In addition, we divided the test period into three 10-min-long
segments to elucidate the temporal trajectories of locomotive parameters. Our preliminary experiments revealed
that the standard deviation of the whole time spent in the light zone of untreated control mice was 120–150 s.

With the type I error rate and power being 5% and 0.80, respectively, if we were to detect a 200-s difference, the
sample size required was calculated as 7–10 subjects in each group.

**Statistical analyses.** All numerical data are expressed as the mean ± SEM. Between-group comparisons
of physiological parameters, CSD-related electrophysiological data and motility-relevant parameters were con-
ducted with Kruskal–Wallis test, followed by Dunn’s multiple comparison test. The two-way repeated-measures
ANOVA was used to evaluate the effects of CSD induction and pharmacological interventions on temporal tra-
jectories of threshold temperature of heat pain, ambulatory time and distance. Post-hoc multiple comparisons
were carried out using Bonferroni’s test. Mean differences were indicated with a 95% CI. Data were analysed
using GraphPad Prism 7 software (GraphPad Software, San Diego, CA).

Received: 6 April 2020; Accepted: 17 June 2020
Published online: 10 July 2020
9. Andersen, A. R., Friberg, L., Olsen, T. S. & Olesen, J. Delayed hyperemia following hypoperfusion in classic migraine. Single photon emission computed tomography demonstration. Ann. Neurol. 12, 469–474. https://doi.org/10.1002/ana.4102510 (1982).

6. Olesen, J. et al. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann. Neurol. 28, 791–798. https://doi.org/10.1002/ana.410280610 (1990).

7. Olesen, J., Larsen, B. & Lauritzen, M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann. Neurol. 9, 344–352. https://doi.org/10.1002/ana.410090406 (1981).

8. Cao, Y., Welch, K. M., Aurora, S. & Vikingstad, E. M. Functional MRI-BOLD of visually triggered headache in patients with migraine. Ann. Neurol. 56, 548–554. https://doi.org/10.1002/anie.20065.548 (1999).

9. Andersen, A. R., Friberg, L., Olsen, T. S. & Olesen, J. Delayed hyperemia following hyperfusion in classic migraine. Single photon emission computed tomographic demonstration. Ann. Neurol. 45, 154–159. https://doi.org/10.1001/archneur.1998.005206004107 (1998).

10. Bowyer, S. M., Aurora, K. S., Moran, J. E., Tepley, N. & Welch, K. M. Magnetoencephalographic fields from patients with spontaneous and induced migraine aura. Ann. Neurol. 50, 582–587 (2001).

11. Hadjikhani, N. et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc. Natl. Acad. Sci. USA 98, 4687–4692. https://doi.org/10.1073/pnas.071582498 (2001).

12. Zhang, X. et al. Activation of meningeal nociceptors by cortical spreading depression: implications for migraine with aura. J. Neurosci. 30, 8807–8814. https://doi.org/10.1523/JNEUROSCI.1011-10.2010 (2010).

13. Zhang, X. et al. Activation of central trigeminovascular neurons by cortical spreading depression. Ann. Neurol. 69, 855–865. https://doi.org/10.1002/ane.22329 (2011).

14. Karatas, H. et al. Spreading depression triggers headache by activating neuronal Panx1 channels. Science 339, 1092–1095. https://doi.org/10.1126/science.1231897 (2013).

15. Noseda, R., Copenhagen, D. & Burstein, R. Current understanding of photophobia, visual networks and headaches. Cephalalgia https://doi.org/10.1177/0333102418784750 (2018).

16. Dechant, K. L. & Clissold, S. P. Sumatriptan: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 43, 776–799. https://doi.org/10.2165/00003495-199243050-00010 (1992).

17. Olesen, J. et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med. 350, 1104–1110. https://doi.org/10.1056/NEJMoat303505 (2004).

18. Ho, T. W. et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70, 1304–1312. https://doi.org/10.1212/01.WNL.0000286940.29753.6f (2008).

19. Cucchiara, R. B., Datì, R., Aguirre, G. K., Idaho, K. E. & Detre, J. A. Measure of visual sensitivity in migraine: validation of two scales and correlation with visual cortex activation. Cephalalgia 35, 585–592. https://doi.org/10.1177/0333102414547782 (2015).

20. Perenboom, M. J. L., Zamanipoor Najafabadi, A. H., Zielman, R., Carpay, J. A. & Ferrari, M. D. Quantifying visual allodynia across migraine subtypes: the Leiden visual sensitivity scale. Pain 159, 2375–2382. https://doi.org/10.1097/J.PAIN.0000015000001343 (2018).

21. Datta, R., Aguirre, G. K., Hu, S., Detre, J. A. & Cucchiara, B. Intercortical cortical hyperexcitability in migraine is directly related to the presence of aura. Cephalalgia 33, 365–374. https://doi.org/10.1177/0333102412474503 (2013).

22. Brighina, F. et al. Visual cortex hyperexcitability in migraine in response to sound-induced flash illusions. Neurology 84, 2057–2061. https://doi.org/10.1212/WNL.0000000000015854 (2015).

23. Tulen, J. H., Stronks, D. L., Bussmann, J. B., Peppinkhuizen, L. & Passchier, J. Towards an objective quantitative assessment of daily functioning in migraine: a feasibility study. Pain 86, 139–149. https://doi.org/10.1016/S0304-3959(00)00235-9 (2000).

24. Zhao, J. & Levy, D. Cortical spreading depression promotes persistent mechanosensitization of intracranial meningeal afferents: implications for the intracranial mechanosensitivity of migraine. J. Neurosci. 37, 776–798. https://doi.org/10.1211/1468-2982.2013.07.021 (2013).

25. Bourin, M. & Hascoet, M. The role of light in migraine. J. Neurosci. 33, 159–204. https://doi.org/10.1016/j.neuroscience.2012.03.002 (2015).

26. Rebec, A. et al. Role of calcitonin gene-related peptide in light-aversive behavior: implications for migraine. J. Neurosci. 29, 8798–8804. https://doi.org/10.1523/JNEUROSCI.1727-09.2009 (2009).

27. Bates, E. A. et al. Sumatriptan alleviates nitroglycerin-induced mechanical and thermal allodynia in mice. Cephalalgia 30, 170–178. https://doi.org/10.1177/0333102410382732 (2010).

28. Mason, B. N. et al. Induction of migraine-like photophobic behavior in mice by both peripheral and central CGRP mechanisms. J. Neurosci. 37, 204–216. https://doi.org/10.1523/JNEUROSCI.2967-16.2017 (2017).

29. Noseda, R. et al. A neural mechanism for exacerbation of headache by light. Nat. Neurosci. 13, 239–245. https://doi.org/10.1038/nn.2475 (2010).
37. Varnas, K., Hall, H., Bonaventure, P. & Sedvall, G. Autoradiographic mapping of 5-HT(1B) and 5-HT(1D) receptors in the post mortem human brain using [(3)H]GR 125743. Brain Res. 915, 47–57. https://doi.org/10.1016/S0006-8993(01)02823-2 (2001).
38. Warfvinge, K. & Edvinsson, L. Distribution of CGRP and CGRP receptor components in the rat brain. Cephalalgia 39, 342–353. https://doi.org/10.1177/0333102417728873 (2019).
39. Warfvinge, K., Edvinsson, L., Pickering, D. S. & Sheykhhazade, M. The presence of calcitonin gene-related peptide and its receptors in rat, pig and human brain: species differences in calcitonin gene-related peptide pharmacology. Pharmacology https://doi.org/10.1159/0009052471 (2019).
40. Ramirez Rosas, M. B., Labrujere, S., Villalon, C. M. & Maassen Vandenbrink, A. Activation of 5-hydroxytryptamine 1B/1D/1F receptors as a mechanism of action of antimigraine drugs. Expert Opin. Pharmacother. 14, 1599–1610. https://doi.org/10.1517/14656662.2013.806487 (2013).
41. Villalon, C. M. & VanDenBrink, A. M. The role of 5-hydroxytryptamine in the pathophysiology of migraine and its relevance to the design of novel treatments. Mini Rev. Med. Chem. 17, 928–938. https://doi.org/10.2174/1389557516666160728121050 (2017).
42. Hou, M. et al. 5-HT(1B) and 5-HT(1D) receptors in the human trigeminal ganglion: co-localization with calcitonin gene-related peptide, substance P and nitric oxide synthase. Brain Res. 909, 112–120. https://doi.org/10.1016/s0006-8993(01)02645-2 (2001).
43. Williamson, D. J., Hargreaves, R. J., Hill, R. G. & Shephard, S. L. Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat-intravital microscope studies. Cephalalgia 17, 525–531. https://doi.org/10.1080/03331021701704525.x (1997).
44. Williamson, D. J., Shephard, S. L., Hill, R. G. & Hargreaves, R. J. The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation. Eur. J. Pharmacol. 328, 61–64. https://doi.org/10.1016/s0014-2999(97)83028-2 (1997).
45. Melo-Carrillo, A. et al. Selective inhibition of trigeminovascular neurons by fremanezumab: a humanized monoclonal anti-CGRP antibody. J. Neurosci. 37, 7149–7163. https://doi.org/10.1523/JNEUROSCI.0576-17.2017 (2017).
46. Melo-Carrillo, A. et al. Fremanezumab—a humanized monoclonal anti-CGRP antibody inhibits thinly myelinated (C) meningeal nociceptors. J. Neurosci. 37, 10587–10596. https://doi.org/10.1523/JNEUROSCI.2211-17.2017 (2017).
47. Humphrey, P. P. et al. Preclinical studies on the anti-migraine drug, sumatriptan. Eur. Neurol. 31, 282–290. https://doi.org/10.1159/000116755 (1991).
48. Kuba, H., Hoskin, K. L. & Goosby, P. J. Inhibition by sumatriptan of central trigeminal neurones only after blood–brain barrier disruption. Br. J. Pharmacol. 109, 788–792. https://doi.org/10.1111/j.1476-5381.1993.tb13643.x (1993).
49. Dodick, D. W. CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications. Cephalalgia 39, 445–458. https://doi.org/10.1177/03331024188121662 (2019).
50. Hounen, T. et al. Optogenetic induction of cortical spreading depression in anesthetized and freely behaving mice. J. Cereb. Blood Flow Metab. 37, 1641–1655. https://doi.org/10.1002/jcbf.13264 (2017).
51. Sachs, M., Pape, H. C., Speckmann, E. J. & Gorji, A. The effect of estrogen and progesterone on spreading depression in rat neo-cortical tissues. Neurobiol. Dis. 25, 27–34. https://doi.org/10.1016/j.nbd.2006.08.013 (2007).
52. Chauvel, V., Schoenen, J. & Multon, S. Influence of ovarian hormones on cortical spreading depression and its suppression by δ-l-kyunurepine in rat. PLoS ONE 8, e82279. https://doi.org/10.1371/journal.pone.0082279 (2013).
53. Ebine, T. et al. Alterations in the threshold of the potassium concentration to evoke cortical spreading depression during the natural estrous cycle in mice. Neurosci. Res. 112, 57–62. https://doi.org/10.1016/j.neures.2016.06.001 (2016).
54. Charles, A. Migraine. N. Engl. J. Med. 377, 553–561. https://doi.org/10.1056/NEJMc1605502 (2017).
55. Dodick, D. W. Migraine. Lancet 391, 1315–1330. https://doi.org/10.1016/s0140-6736(18)30478-1 (2018).
56. Unekawa, M., Ikeda, K., Tomita, Y., Kawakami, K. & Suzuki, N. Enhanced susceptibility to cortical spreading depression in two types of Na(+), K(+)-ATPase alpha2 subunit-deficient mice as a model of familial hemiplegic migraine 2. Cephalalgia 38, 1515–1524. https://doi.org/10.1177/0333102417738249 (2018).
57. Blumstein, L. K. & Crawley, J. N. Further characterization of a simple, automated exploratory model for the anxiolytic effects of benzodiazepines. Pharmacol. Biochem. Behav. 18, 37–40. https://doi.org/10.1016/0091-3057(83)90247-2 (1983).
58. Onaivi, E. S. & Martin, B. R. Neuropharmacological and physiological validation of a computer-controlled two-compartment black and white box for the assessment of anxiety. Prog. Neuropsychopharmacol. Biol. Psychiatry 13, 963–976. https://doi.org/10.1016/s0278-5846(89)90047-x (1989).

Acknowledgements
The authors thank Prof. Eiichiro Nagata at the Department of Neurology, Tokai University, Kanagawa, Japan and Prof. Motoharu Takao at the Department of Human and Information Science, Tokai University, Kanagawa, Japan for their suggestions and insightful discussion. This study was supported by JSPS KAKENHI (Grant No. 19K07849, to MS), a Grant from the Takeda Science Foundation to MS, and research grants from Pfizer Inc. (WS1878886), Nippon Zoki Pharmaceutical Co., Ltd. and Kao Corporation to our research group. This work was supported in part by a Japan–China Sasakawa Medical Fellowship (2017816) and a State Scholarship Fund of the China Scholarship Council (201908500072) to CT.

Author contributions
MS conceived the research. MS and CT designed and performed the experiments and wrote the manuscript. MU performed the experiments and edited the manuscript. SK and YK performed the experiments. TT and JN edited the manuscript. MS was involved in the coordination of contributors. All authors read and approved the final manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-67948-w.
Correspondence and requests for materials should be addressed to M.S.
Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
